Filter By:

Reset
ACS and Interventional Cardiology Research

We have spent two decades focusing on how, when and where to best treat heart attacks, a form of acute coronary syndromes (ACS) – from assessing if early coronary intervention benefits high-risk patients, to evaluating anti-inflammatory and aldosterone-block drugs in ACS patients, and more. Landmark studies in the ACS program include COMPLETE, RIVAL, AND OASIS 4 (CURE).

Shamir Mehta

Senior Scientist

Shamir Mehta
Senior Scientist

Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI. He holds the Douglas A. Holder Endowed Chair and is a Professor of Medicine at McMaster University. Mehta directs the Royal College fellowship in interventional cardiology and leads the mitral and tricuspid valve transcatheter edge-to-edge repair programs at Hamilton Health Sciences and McMaster University. He completed his medical education and postgraduate training at the University of Toronto, followed by a research fellowship at McMaster University, supported by a Canadian Institutes of Health Research New Investigator Award.

At PHRI, he leads landmark clinical trials that evaluate revascularization strategies and new pharmacologic interventions for patients with acute coronary syndromes. Mehta is the Principal Investigator of the COMPLETE-2 trial, a 5,100-patient multinational study comparing physiology-guided and angiography-guided PCI strategies for treating non-culprit lesions in patients with acute coronary syndrome and multivessel coronary artery disease. This trial includes a large-scale intracoronary imaging study using optical coherence tomography to predict cardiovascular events. He also serves on the executive committee of the Librexia ACS trial, which is testing a novel Factor XIa inhibitor in acute coronary syndromes, and he is a steering committee member of OCEAN(a), focusing on targeted lowering of lipoprotein(a) with a novel small interfering RNA after acute coronary syndrome or PCI.

Dr. Mehta has published hundreds of research articles and has secured millions of dollars in peer-reviewed research grants from CIHR and industry. In 2022, he received the Canadian Cardiovascular Society’s Research Achievement Award. In 2024, he received the Canadian Association of Interventional Cardiology Outstanding Achievement Award.

Sanjit Jolly

Scientist

Sanjit Jolly
Scientist

Sanjit Jolly is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University. He has formal training in clinical trials with a M.Sc. in Health Research Methodology from McMaster. He was the principal investigator of the RIVAL trial, a randomized trial of 7021 patients comparing radial and femoral access for coronary intervention. He is also the principal investigator trial of the ongoing TOTAL trial, an international randomized trial (N=10,700) of thrombectomy during primary PCI.

Madhu Natarajan

Investigator

Madhu Natarajan
Investigator

Madhu Natarajan is an interventional cardiologist and Principal Investigator for the Coronary Interventional Health Delivery and Knowledge Translational and Implementation programs at PHRI. He is a Professor at McMaster University, Director of Catheterization Laboratories at Hamilton Health Sciences, and Site Director for Cardiology at Hamilton General Hospital.

He has published more than 85 articles, is Chair of the STEMI-EMS Committee, Cardiac Care Network of Ontario, member of the Royal College Cardiology National Examination Board, and program lead for Regional STEMI network in LHIN-4 Ontario.

JD Schwalm

Scientist

JD Schwalm
Scientist

JD Schwalm is a Scientist in the Knowledge Translation and Health Systems research program at PHRI, an Associate Professor, Department of Medicine at McMaster University, and an Interventional Cardiologist at Hamilton Health Sciences (HHS) and Niagara Health. Schwalm is also the site lead for Cardiology at the Hamilton General Hospital and the Director of the Centre for Evidence-Based Implementation (www.hhsCEBI.ca), HHS.

Schwalm completed medical school, Internal Medicine residency, and Cardiology and Interventional Cardiology fellowship training at McMaster University, Ontario. He also did further Interventional Training and a Master of Science in Epidemiology, with an interest in Knowledge Translation at the University of Ottawa. He is a fellow of the Royal College of Physicians and Surgeons of Canada, with certification in Internal Medicine and Cardiology.   

His research, supported by CIHR, The Ministry of Health (Ontario), HAHSO, WHO, and WHF, focuses on Knowledge Translation/Implementation Sciences as it relates to the field of cardiology at the patient, physician, and health system level. Schwalm has authored more than 95 peer-reviewed publications, including high-impact journals (i.e. The Lancet and BMJ). 

Tej Sheth

Scientist

Tej Sheth
Scientist

Tej Sheth is a Scientist with the Perioperative and Surgery research program at PHRI, as well as a Principal Investigator in atherosclerosis imaging, an Associate Professor in the Department of Medicine at McMaster University, and a interventional cardiologist at Hamilton Health Sciences. His research interests include invasive and non-invasive coronary imaging modalities, including coronary angiography, optical coherence tomography, and CT coronary angiography. He is Director of the CT Angiographic Core Lab for the COMPASS CABG study and the COMPLETE trial at PHRI.

completed

Heart Catherization Registry

Interventional Cardiology

The objective of the Heart Catherization Registry was to quantify the waiting times, morbidity and...

completed

OASIS Registry

Interventional Cardiology

The objective of the OASIS Registry was to evaluate the variations between countries in invasive...

completed

OASIS 1

Interventional Cardiology

To compare hirudin versus heparin administered as a 72-hour infusion post presentation, and warfarin versus...

completed

OASIS 2

Interventional Cardiology

The objective of the OASIS 2 study was to evaluate if the recombinant hirudin (lepirudin),...

completed

OASIS 3 CREATE

Interventional Cardiology

The objective of THE OASIS 3 CREATE study was to evaluate the effects of reviparin,...

completed

OASIS 3 CREATE – ECLA

Interventional Cardiology

The objective of OASIS 3 CREATE-ECLA was to evaluate the effects of high-dose glucose, insulin,...

Back To Top